Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saban Elitok

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
VASA. Zeitschrift Fur Gefasskrankheiten|January 18, 2021
Inferior vena cava-syndromePeter Franz Klein-Weigel, Saban Elitok, Andreas Ruttloff, et al.
Circulation|May 28, 2009
Regulatory T cells ameliorate angiotensin II-induced cardiac damageHeda Kvakan, Markus Kleinewietfeld, Fatimunnisa Qadri, et al.
American Journal of Physiology. Cell Physiology|March 20, 2025
Effects of high salt intake on glucose metabolism, liver function, and the microbiome in rats: influence of ACE inhibitors and angiotensin II receptor blockersXiaoli Zhang, Mohamed M S Gaballa, Ahmed A Hasan, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 6, 2022
Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion modelChang Chu, Denis Delić, Jana Alber, et al.
Hypertension (Dallas, Tex. : 1979)|August 19, 2015
Clinical effects of phosphodiesterase 3A mutations in inherited hypertension with brachydactylyOkan Toka, Jens Tank, Carolin Schächterle, et al.
Journal of the American College of Cardiology|January 14, 2012
Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort studyThomas L Nickolas, Kai M Schmidt-Ott, Pietro Canetta, et al.
Blood Advances|July 8, 2020
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTPLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood Advances|July 8, 2020
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood|February 11, 2026
Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic PurpuraLucas Kühne, Thomas Osterholt, Maximilian Suer, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
VASA. Zeitschrift Fur Gefasskrankheiten|January 18, 2021
Inferior vena cava-syndromePeter Franz Klein-Weigel, Saban Elitok, Andreas Ruttloff, et al.
Circulation|May 28, 2009
Regulatory T cells ameliorate angiotensin II-induced cardiac damageHeda Kvakan, Markus Kleinewietfeld, Fatimunnisa Qadri, et al.
American Journal of Physiology. Cell Physiology|March 20, 2025
Effects of high salt intake on glucose metabolism, liver function, and the microbiome in rats: influence of ACE inhibitors and angiotensin II receptor blockersXiaoli Zhang, Mohamed M S Gaballa, Ahmed A Hasan, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 6, 2022
Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion modelChang Chu, Denis Delić, Jana Alber, et al.
Hypertension (Dallas, Tex. : 1979)|August 19, 2015
Clinical effects of phosphodiesterase 3A mutations in inherited hypertension with brachydactylyOkan Toka, Jens Tank, Carolin Schächterle, et al.
Journal of the American College of Cardiology|January 14, 2012
Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort studyThomas L Nickolas, Kai M Schmidt-Ott, Pietro Canetta, et al.
Blood Advances|July 8, 2020
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTPLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood Advances|July 8, 2020
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood|February 11, 2026
Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic PurpuraLucas Kühne, Thomas Osterholt, Maximilian Suer, et al.
Pageof 6